Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 288

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy

Open access
Marso, Steven P., Lincoff, A. Michael, Ellis, Stephen G., Bhatt, Deepak L., Tanguay, Jean-Francois, Kleiman, Neal S., Hammoud, Talal, Booth, Joan E., Sapp, Shelly K., Topol, Eric J.·1999·Circulation

Abstract

Background —Stenting likely decreases the need for target-vessel revascularization procedures in diabetic patients compared with balloon angioplasty. However, the efficacy of stenting with platelet glycoprotein IIb/IIIa blockade has not yet been assessed in diabetics. Methods and Results —We analyzed the outcomes of 491 diabetic patients within the multicenter Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT). Diabetic patients were a prospectively defined subset: 173 were randomized to stent-placebo, 162 to stent-abciximab, and 156 to balloon angioplasty–abciximab. The main end point for this analysis was combined 6-month death, myocardial infarction (MI), or target-vessel revascularization (TVR). The composite end point occurred in 25.2% of stent-placebo, 23.4% of balloon-abciximab, and 13.0% of stent-abciximab patients ( P =0.005). Abciximab therapy, irrespective of revascularization strategy (stent or balloon angioplasty), resulted in a significant reduction in the 6-month death or MI rate: 12.7% for stent-placebo, 7.8% for balloon angioplasty–abciximab, and 6.2% for the stent-abciximab group ( P =0.029). The 6-month TVR rate was 16.6% for stent-placebo, 18.4% for balloon-abciximab, and 8.1% for stent-abciximab ( P =0.021). Compared with stent-placebo, stent-abciximab therapy was associated with a significant increase in angiographic net gain (0.88 versus 0.55 mm; P =0.011) and a decrease in the late loss index (0.40 versus 0.60 mm; P =0.061). The 1-year mortality rate for diabetics was 4.1% for stent-placebo and 1.2% for stent-abciximab patients ( P =0.11). Conclusions —The combination of stenting and abciximab therapy among diabetics resulted in a significant reduction in 6-month rates of death, MI, and TVR compared with stent-placebo or balloon-abciximab therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.100.25.2477

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 288

Metadata

Authors
Marso, S. P., Lincoff, A. M., Ellis, S. G., Bhatt, D. L., Tanguay, J.-F., Kleiman, N. S., Hammoud, T., Booth, J. E., Sapp, S. K., & Topol, E. J.
Venue
Circulation
Published
1999-12-21
Volume
100
Issue
25
Pages
2477-2484
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2120786522
Cited by
288
References
25
FWCI
29.19
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy. https://app.cochat.ai/papers/10.1161/01.cir.100.25.2477
The paper
Marso, S. P., Lincoff, A. M., Ellis, S. G., Bhatt, D. L., Tanguay, J.-F., Kleiman, N. S., Hammoud, T., Booth, J. E., Sapp, S. K., & Topol, E. J. (1999). Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy. Circulation. https://doi.org/10.1161/01.cir.100.25.2477

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.